{"created":"2023-06-19T10:43:10.747609+00:00","id":3343,"links":{},"metadata":{"_buckets":{"deposit":"512b6a07-cddd-4bd4-9135-592bcbf6528a"},"_deposit":{"created_by":11,"id":"3343","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"3343"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00003343","sets":["30:50:193"]},"author_link":["3728","2767","2737","7444","2502","6625","4468","3212"],"item_4_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-12","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"180","bibliographicPageStart":"175","bibliographicVolumeNumber":"9","bibliographic_titles":[{"bibliographic_title":"Clinical ophthalmology"}]}]},"item_4_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"伊藤, 友香"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"西信, 良嗣"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"澤田, 修"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"柿木, 雅志"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"三宅, 太一郎"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"澤田, 智子"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"川村, 肇"}],"nameIdentifiers":[{},{}]}]},"item_4_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Our aim was to compare the 1 year efficacy and safety results of intravitreal bevacizumab (IVB) in two prospective, consecutive groups of patients with macular edema (ME) following branch retinal vein occlusion (BRVO).\nTwenty-five eyes with ME after BRVO received one IVB injection (single-injection group) and 27 eyes received three monthly IVB injections (three-injection group). Both groups were followed monthly for 12 months. The best-corrected visual acuity (BCVA) and the central foveal thickness (CFT) on optical coherence tomography were evaluated before and after treatment. Patients were eligible to receive an IVB injection if the mean CFT increased 100 μm or more or the BCVA decreased 0.1 logarithm of the minimum angle of resolution (logMAR) unit or more compared with values measured on the last visit.\nThe mean logMAR BCVA and CFT, respectively, improved from 0.56 to 0.33 and from 598 μm to 348 μm in the single-injection group (P<0.001) and from 0.55 to 0.26 and from 514 μm to 293 μm in the three-injection group (P<0.001). During the study period, the mean total number of injections was significantly smaller in the single-injection group than in the three-injection group (2.1 and 4.3, respectively, P<0.001). No serious complications related to the IVB injections developed in either group.\nThe single-injection group achieved similar visual outcomes for ME secondary to BRVO with fewer injections compared with the three-injection group.","subitem_description_type":"Abstract"}]},"item_4_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Journal Article","subitem_description_type":"Other"}]},"item_4_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Dove Medical Press"}]},"item_4_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"25657578","subitem_relation_type_select":"PMID"}}]},"item_4_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.2147/OPTH.S76261","subitem_relation_type_select":"DOI"}}]},"item_4_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2015 Ito et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php"}]},"item_4_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1177-5467","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"ITO, Yuka"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"SAISHIN, Yoshitsugu"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"SAWADA, Osamu"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"KAKINOKI, Masashi"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"MIYAKE, Taichiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"SAWADA, Tomoko"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"KAWAMURA, Hajime"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"OHJI, Masahito"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-12-06"}],"displaytype":"detail","filename":"OPTH.S76261.pdf","filesize":[{"value":"380.8 kB"}],"format":"application/pdf","licensetype":"license_9","mimetype":"application/pdf","url":{"label":"OPTH.S76261.pdf","url":"https://shiga-med.repo.nii.ac.jp/record/3343/files/OPTH.S76261.pdf"},"version_id":"f30d48ac-b7c1-45e5-8f8a-fff425b925be"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"branch retinal vein occlusion","subitem_subject_scheme":"Other"},{"subitem_subject":"bevacizumab","subitem_subject_scheme":"Other"},{"subitem_subject":"single intravitreal injection","subitem_subject_scheme":"Other"},{"subitem_subject":"three monthly intravitreal injections","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion."}]},"item_type_id":"4","owner":"11","path":["193"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-12-06"},"publish_date":"2018-12-06","publish_status":"0","recid":"3343","relation_version_is_last":true,"title":["Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion."],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-06-19T12:09:03.395539+00:00"}